Journal Reviews
Cystoid macular oedema following retinal detachment surgery
There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...
OCT biomarkers in asymmetric anti-VEGF response in bilateral diabetic macular oedema
This study aimed to identify optical coherence tomography (OCT) biomarkers for predicting response to anti-VEGF treatment in diabetic macular oedema (DMO). Bilateral DMO patients with asymmetric response to a loading dose of anti-VEGF (ranibizumab / aflibercept) treatment were retrospectively studied....
Outcomes of treat & extend ranibizumab in diabetic macular oedema
This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...
Steroid treatment for pseudophakic cystoid macular oedema
The authors present a retrospective comparison of 45 eyes of 41 patients treated with 2mg intravitreal triamcinolone (IVT group) and 50 eyes of 42 patients treated with 40mg sub-Tenons triamcinolone (STT group) for pseudophakic cystoid macular oedema (CMO). The visual...
Transient macular thinning with Densiron 68
Densiron 68 is a heavy silicone oil (HSO) used to treat rhegmatogenous retinal detachments (RRD) with inferior retinal breaks. The authors compared changes in retinal thickness during and after the use of Densiron endotamponade, and looked at any association between...
The effects of anti-VEGF therapy for NvAMD on retinal vasculature
This retrospective consecutive case series examined 54 eyes of 54 treatment-naïve neovascular age-related macular degeneration (N-AMD) patients. Thirty-three eyes received intravitreal aflibercept injections, and 21 eyes received intravitreal ranibizumab injections with unaffected fellow eyes (54 eyes) as controls. All image...
OCTA in geographic atrophy
In this article the authors aim to give an overview of the current literature concerning the application of OCT-A in geographic atrophy (GA). GA is a disease characterised by loss of outer retinal layers including photoreceptors, degeneration of the retinal...
Wet AMD outcomes post cataract surgery
The authors present the findings of a retrospective study looking at the progression of wet age-related macular degeneration (AMD) in patients who underwent cataract surgery. They recruited a series of 111 patients of which 38 were men and 73 were...
Characteristics of Charles Bonnet syndrome in patients with neovascular AMD
This retrospective cross-sectional study aimed to characterise various aspects of Charles Bonnet syndrome hallucinations among patients with neovascular age-related macular degeneration (AMD). Five hundred and ten consecutive patients were asked a screening question to determine if they had ever suffered...
Changes in drusen and retinal layer volumes prior to CNV development
This retrospective longitudinal study looked at patients with wet age-related macular degeneration (AMD) in one eye who subsequently developed wet AMD in the fellow eye. The aim was to discover whether drusen characteristics or volumes of retinal layers correlate with...
Effect of blue-light filtering intraocular lenses on age-related macular degeneration
This is a retrospective cohort study evaluating whether blue-light filtering (BLF) intraocular lenses (IOL) offer prophylaxis for neovascular age-related macular degeneration (nAMD). The study included 11,397 eyes of 11,397 patients with a mean age of 75.4 ±8.3 years that underwent...
Intravitreal Ziv-Aflibercept: safety analysis
Ziv-Aflibercept (Zaltrap; Sanofi-Aventis U.S LLS, Bridgewater, NJ) was originally introduced as an intravenous formulation for metastatic colorectal cancer. The adoption of Ziv-Aflibercept in ophthalmic practice was similar to bevacizumab, and reports have previously examined one to two year visual outcomes...
